stockportfolio.pro
Vericel Corporation (VCEL)
Healthcare · Biotechnology · NasdaqGM
Vericel Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.38M | $63.92M | $90.86M | $117.85M | $124.18M | $156.18M | $164.37M | $197.52M | $237.22M | $276.26M |
| Gross profit | $26.08M | $33.57M | $58.70M | $80.28M | $84.23M | $106.03M | $109.79M | $135.58M | $172.11M | $205.60M |
| Net income | $-19.57M | $-17.29M | $-8.14M | $-9.66M | $2.86M | $-7.47M | $-16.71M | $-3.18M | $10.36M | $16.52M |
| Net margin | -36.0% | -27.0% | -9.0% | -8.2% | 2.3% | -4.8% | -10.2% | -1.6% | 4.4% | 6.0% |
Source: Vericel Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Vericel Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VCEL in your portfolio →
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Vericel Corporation — frequently asked questions
What is Vericel Corporation's revenue?
Vericel Corporation (VCEL) reported revenue of $276.26M for fiscal year 2025, up 16.5% from the prior year, according to its SEC filings.
Is Vericel Corporation profitable?
Yes. VCEL earned net income of $16.52M in fiscal 2025, a net margin of 6.0%.
What is VCEL's P/E ratio?
Vericel Corporation trades at a price-to-earnings ratio of about 86.6 based on the latest data in our nightly-refreshed cache.
How fast is Vericel Corporation growing?
VCEL's revenue grew at roughly 17.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Vericel Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.